Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
Torben Plesner(University of Southern Denmark), Paul G. Richardson(Dana-Farber Cancer Institute), Linda Basse(Genmab (Denmark)), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), A. Kate Sasser(Janssen (United States)), Steen Lisby(Genmab (Denmark)), Charlotte Lemech, Carla de Boer(Janssen (Netherlands)), Monique C. Minnema(University Medical Center Utrecht), Jacob P. Laubach(Harvard University), Mary Guckert(GlaxoSmithKline (United States)), Antonio Palumbo(Azienda Ospedaliero Universitaria San Giovanni Battista), Pamela L. Clemens(Janssen (United States)), Ulrik Lassen(Rigshospitalet), Tahamtan Ahmadi(Genmab (United States)), Nushmia Z. Khokhar(Janssen (United States)), Jianping Wang(Sun Yat-sen University), Henk M. Lokhorst(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Peter Gimsing(University of Copenhagen), Howard Yeh(Covance (United States)), Jakub Krejcik(University of Southern Denmark)
Cited by 110
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k